1/23/2008 9:43:18 AM ET
CALGARY, AB --- January 23, 2008 -
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (“Oncolytics”) has been granted Canadian Patent 2,508,238 entitled “Reovirus for the Treatment of Neoplasia.” The claims describe using various human reoviruses to treat cancers that have inactivated or deleted PKR, a host cellular protein responsible for preventing virus replication within a cell.
“This is a broad patent that expands our coverage in Canada in the area of cancers with inactivated PKR,” said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. “Oncolytics secured a similar patent in the U.S. in late 2007.”
About Oncolytics Biotech Inc.Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN®, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics please visit www.oncolyticsbiotech.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment